Biomarkers for nasopharyngeal carcinoma

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-03-19 DOI:10.1016/j.cca.2025.120257

Hsun-Ting Hsieh , Xin-Yao Zhang , Yi Wang , Xin-Qi Cheng

{"title":"Biomarkers for nasopharyngeal carcinoma","authors":"Hsun-Ting Hsieh , Xin-Yao Zhang , Yi Wang , Xin-Qi Cheng","doi":"10.1016/j.cca.2025.120257","DOIUrl":null,"url":null,"abstract":"<div><div>Nasopharyngeal Carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, particularly in China and Indonesia. According to the World Health Organization’s global cancer statistics in 2022, there were 120,434 new cases and 73,485 deaths from NPC. Risk factors contribute to NPC development including genetic factors, dietary habits, and Epstein-Barr virus (EBV) infection. This paper reviews the comparison of different types of EBV test for NPC over the last few years and summarized the performance of novel diagnostic biomarker such as newly reported EBV antibody, anti-BNLF2b IgG (P85-Ab), microRNAs, DNA methylation and other markers for detection of NPC. Because approximately 40% of NPC patients show negative EBV DNA levels, additional markers are needed for NPC diagnosis, especially in cases without EBV infection, to make the result trustworthy. The potential biomarkers including circulating tumor cells, proteins, microRNAs and Rta-IgG for prognostic and therapeutic effect also be summarized. This review provides insights into potential biomarkers for early NPC detection and diagnosis, which could lead to improved prevention, treatment, and prognosis strategies.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"572 ","pages":"Article 120257"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001366","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Nasopharyngeal Carcinoma (NPC) is a malignant tumor that is highly prevalent in Southeast Asia, particularly in China and Indonesia. According to the World Health Organization’s global cancer statistics in 2022, there were 120,434 new cases and 73,485 deaths from NPC. Risk factors contribute to NPC development including genetic factors, dietary habits, and Epstein-Barr virus (EBV) infection. This paper reviews the comparison of different types of EBV test for NPC over the last few years and summarized the performance of novel diagnostic biomarker such as newly reported EBV antibody, anti-BNLF2b IgG (P85-Ab), microRNAs, DNA methylation and other markers for detection of NPC. Because approximately 40% of NPC patients show negative EBV DNA levels, additional markers are needed for NPC diagnosis, especially in cases without EBV infection, to make the result trustworthy. The potential biomarkers including circulating tumor cells, proteins, microRNAs and Rta-IgG for prognostic and therapeutic effect also be summarized. This review provides insights into potential biomarkers for early NPC detection and diagnosis, which could lead to improved prevention, treatment, and prognosis strategies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.